Company Update: AbbVie Inc (NYSE:ABBV) – AbbVie Announces Plans to Proceed to Phase 3 Evaluation of Elagolix in Patients with Uterine Fibroids

[PR Newswire] – NORTH CHICAGO, Ill., Sept. 16, 2015 /PRNewswire/ — AbbVie (ABBV), in cooperation with Neurocrine Biosciences, Inc. (NBIX), today announced the completion of a Phase 2b clinical trial evaluating the safety . . . → Read More: Company Update: AbbVie Inc (NYSE:ABBV) – AbbVie Announces Plans to Proceed to Phase 3 Evaluation of Elagolix in Patients with Uterine Fibroids Similar Articles: Company Update: AbbVie Inc (NYSE:ABBV) – AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment-Naive Chronic Lymphocytic Leukemia Market Update: AbbVie Inc (NYSE:ABBV) – AbbVie Presents Phase 2 Results from Study of Investigational Medicine Veliparib in Patients with Non-Small Cell Lung Cancer at the American Society of Clinical Oncology Annual Meeting Stock Update: AbbVie Inc (NYSE:ABBV) – AbbVie Announces Expiration of Hart-Scott-Rodino Waiting Period for AbbVie’s Acquisition of Pharmacyclics